JPWO2020143720A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020143720A5 JPWO2020143720A5 JP2021538762A JP2021538762A JPWO2020143720A5 JP WO2020143720 A5 JPWO2020143720 A5 JP WO2020143720A5 JP 2021538762 A JP2021538762 A JP 2021538762A JP 2021538762 A JP2021538762 A JP 2021538762A JP WO2020143720 A5 JPWO2020143720 A5 JP WO2020143720A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- antibody
- seq
- domain
- vegfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910023522.6A CN111423512B (zh) | 2019-01-10 | 2019-01-10 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| CN201910023522.6 | 2019-01-10 | ||
| PCT/CN2020/071213 WO2020143720A1 (zh) | 2019-01-10 | 2020-01-09 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517920A JP2022517920A (ja) | 2022-03-11 |
| JPWO2020143720A5 true JPWO2020143720A5 (https=) | 2024-03-12 |
| JP2022517920A5 JP2022517920A5 (https=) | 2024-03-12 |
Family
ID=71521813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538762A Ceased JP2022517920A (ja) | 2019-01-10 | 2020-01-09 | 血管内皮細胞の増殖をブロックし、ｔ細胞を活性化する多標的融合タンパク質、およびそれを含有する医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220106389A1 (https=) |
| EP (1) | EP3909986A4 (https=) |
| JP (1) | JP2022517920A (https=) |
| CN (1) | CN111423512B (https=) |
| WO (1) | WO2020143720A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283522B2 (en) | 2018-12-03 | 2025-03-01 | Agensys Inc | Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them |
| KR20220107257A (ko) * | 2020-03-20 | 2022-08-02 | 레메젠 코, 리미티드 | 이중특이성 융합 단백질 및 그의 응용 |
| WO2021238904A1 (zh) * | 2020-05-25 | 2021-12-02 | 北京比洋生物技术有限公司 | Fc-CD80融合蛋白和其缀合物以及它们的用途 |
| CN116209466A (zh) * | 2020-08-27 | 2023-06-02 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗鼻咽癌中的用途 |
| CN113480614B (zh) * | 2021-08-13 | 2023-01-10 | 中国人民解放军总医院 | 一类靶向pd-l1的超高亲和力小蛋白及用途 |
| JP2025508267A (ja) * | 2022-03-04 | 2025-03-21 | パノロス バイオサイエンス インコーポレイテッド | ＶＥＧＦ－Ｇｒａｂ及びＰＤ－１又はＰＤ－Ｌ１拮抗剤を含む併用投与用組成物 |
| IL318220A (en) * | 2022-07-25 | 2025-03-01 | Agensys Inc | Methods for treating patients with locally advanced or metastatic urinary tract cancer with antibody drug conjugates (ADCs) that bind 191P4D12 proteins in combination with pembrolizumab |
| TW202413427A (zh) * | 2022-08-09 | 2024-04-01 | 大陸商上海濟煜醫藥科技有限公司 | 一種靶向ｐｄ－１和ｖｅｇｆ的抗體及其應用 |
| JP2025534252A (ja) * | 2022-09-14 | 2025-10-15 | 尋済生物科技（北京）有限公司 | 抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用 |
| CN116102624B (zh) * | 2023-03-07 | 2025-10-03 | 南京中医药大学 | 一种具有抑制血管生成作用的线性多肽及其环肽 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1916001T1 (sl) * | 2002-03-04 | 2011-10-28 | Imclone Llc | Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| BRPI0913366A8 (pt) * | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
| EP2435477A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
| PE20120622A1 (es) * | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2646007B1 (en) * | 2010-12-02 | 2016-12-21 | Neurotech USA, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| SG10201900002QA (en) * | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CN104195173B (zh) | 2014-09-02 | 2017-03-08 | 北京比洋生物技术有限公司 | 具有双表达盒的谷氨酰胺合成酶高效表达载体 |
| WO2017025498A1 (en) * | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
| AU2016350701B2 (en) * | 2015-11-02 | 2021-08-19 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| CN109069638B (zh) * | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| CN109563124A (zh) * | 2016-06-17 | 2019-04-02 | 豪夫迈·罗氏有限公司 | 多特异性抗体的纯化 |
| EP3596114A2 (en) * | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| AU2018250641B2 (en) * | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
-
2019
- 2019-01-10 CN CN201910023522.6A patent/CN111423512B/zh active Active
-
2020
- 2020-01-09 WO PCT/CN2020/071213 patent/WO2020143720A1/zh not_active Ceased
- 2020-01-09 US US17/421,874 patent/US20220106389A1/en not_active Abandoned
- 2020-01-09 JP JP2021538762A patent/JP2022517920A/ja not_active Ceased
- 2020-01-09 EP EP20738951.1A patent/EP3909986A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12258418B2 (en) | Claudin18.2 binding moieties and uses thereof | |
| JP6124377B2 (ja) | 新規抗ｄｒ５抗体 | |
| JP2021526816A (ja) | Ｄｌｌ３−ｃｄ３二重特異性抗体 | |
| EP4393950A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| US20250382373A1 (en) | Anti-egfr/met antibodies and uses thereof | |
| KR20210132664A (ko) | 항pd-l1 항체 및 그의 용도 | |
| CA3208455A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2024001073A5 (https=) | ||
| JP2024503297A (ja) | 多重特異性抗原結合タンパク質 | |
| JPWO2020143720A5 (https=) | ||
| US20250059297A1 (en) | Anti-her2/trop2 antibodies and uses thereof | |
| JPWO2021041878A5 (https=) | ||
| CA3119458A1 (en) | Methods and monitoring of treatment with vegf/dll4 binding agent | |
| US20220135686A1 (en) | Antibody that binds to human pd-l1 | |
| JP2025527160A (ja) | 多重特異性抗体およびその使用 | |
| JPWO2023051683A5 (https=) | ||
| JPWO2022253314A5 (https=) | ||
| WO2026067461A1 (en) | Multispecific antibody protein and uses thereof | |
| US20260109769A1 (en) | Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use | |
| EP4524248A1 (en) | Anti-taa/anti-cd3 multispecific antibody | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| HK40052157A (en) | Anti-pd-l1 antibody and use thereof | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 | |
| CN120271715A (zh) | 抗体及其药物偶联物和用途 |